Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Vantive AB
AB
Active
Org 5594399106
Kista
Manufacture of pharmaceutical preparations
·
NACE 2120
Est. 2023 · 2 years old
20-49 employees
Monitor
Share
Sweden
/
Companies
/
Manufacture of pharmaceutical preparations
/
Vantive AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
98M
195M
293M
391M
340M
2024
EBITDA
SEK millions
13M
9M
6M
3M
0M
10M
2024
Income statement
SEK thousands
Item
2024
Revenue
340 437
Staff expenses
—
EBITDA
10 440
Depreciation & amort.
−5 557
EBIT
4 883
Net financials
447
Profit before tax
2 557
Tax
−811
Net profit
1 746
Balance sheet
SEK thousands
Item
2024
Total assets
152 883
Equity
19 891
Long-term debt
0
Short-term debt
130 219
Total debt
130 219
Financial ratios
5-year trend
EBITDA margin
3.1%
This company
15.8%
Market median
-80% vs market
2024
2024
Equity ratio
13.0%
This company
38.2%
Market median
-66% vs market
2024
2024
Return on equity
8.8%
This company
18.4%
Market median
-52% vs market
2024
2024
Net profit margin
0.5%
This company
8.1%
Market median
-94% vs market
2024
2024
Asset turnover
2.23×
This company
1.12×
Market median
+99% vs market
2024
2024
Debt / equity
6.69×
This company
0.62×
Market median
-979% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-12-31
View
PDF
More on Vantive AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network